About: Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) наукова стаття, опублікована в серпні 2009 (uk) im August 2009 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q57423409-68E66E88-4A2E-475C-BB4F-F7265CFDDFAD
publication date	2009-08-04 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57423409-CE7924A8-FEDF-4E40-93CA-7C6278A18BC4
language of work or name	English
cites work	wds:Q57423409-5FE1E95D-CA49-4AAD-9319-60B093E1E72A
cites work	Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies
author name string	wds:Q57423409-29B5FE03-091C-4925-8166-CA6F0D7926F0 wds:Q57423409-37FB5C6A-E32D-46E8-A727-D9D80DCC2938 wds:Q57423409-39093AAB-F10F-4A81-982E-E91A405F4982 wds:Q57423409-3ADAE66F-7502-47CE-A05A-7CE5B3FDB65D wds:Q57423409-A56C36E9-8F69-45B5-A1DE-5A95DDE954D5 wds:Q57423409-D2B372E8-178F-4C7D-913F-CC8D6F2A2E35
author name string	J. Jonkers P. Borst A. Kersbergen A. O.H. Nygren E. van der Burg J. K. Iyer
rdfs:label	Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer (en) Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer (nl)
skos:prefLabel	Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer (en) Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer (nl)
name	Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer (en) Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer (nl)
author	wds:Q57423409-22AD625C-797B-4B13-8052-83353B926414 wds:Q57423409-82587E61-DB11-4DAA-A2B1-E1BEDAC88036
author	Marina Pajic Sven Rottenberg
title	wds:Q57423409-D3279A54-0A8D-45E9-A2AB-D8C5AAFB87A7
title	Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer (en)
page(s)	wds:Q57423409-5CA57FE9-DF0D-415F-ADD8-D7E871897497
page(s)	6396-6404
instance of	wds:Q57423409-497A67DD-5DEB-48CB-ADA8-C4A1BDE985BE
instance of	scholarly article
main subject	wds:Q57423409-5F7F0558-7C09-43C2-9DC6-3F45526B22A8 wds:Q57423409-7348F3E5-9584-448C-920F-F7E156EBBA93
main subject	wd:Q18936 breast cancer
PubMed ID	wds:Q57423409-EB1D3CF3-B67D-4B2D-8608-F19D9F316A78
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19654309
PubMed ID	19654309
published in	wds:Q57423409-011F078B-1EA4-4538-8508-9641D4453712
published in	Cancer Research
issue	wds:Q57423409-285717A2-D276-471E-A020-A2FFF3847A8B
volume	wds:Q57423409-5B2B6BB2-FEA9-4E5A-AB37-60113E51F461
issue	16
volume	69
DOI	wds:Q57423409-7184A5E1-0E6C-472E-B15A-3FA8EC62D946
DOI	http://dx.doi.org/10.1158/0008-5472.CAN-09-0041
DOI	10.1158/0008-5472.CAN-09-0041
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57423409
is cites work of	Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1 Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'. Cellular robustness conferred by genetic crosstalk underlies resistance against chemotherapeutic drug doxorubicin in fission yeast Multidrug resistance in breast cancer: from in vitro models to clinical studies Modeling and predicting clinical efficacy for drugs targeting the tumor milieu Mechanisms of resistance to PARP inhibitors--three and counting. Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents? Ultrasound/Magnetic Targeting with SPIO-DOX-Microbubble Complex for Image-Guided Drug Delivery in Brain Tumors. ABC transporters: unvalidated therapeutic targets in cancer and the CNS P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance Tuning the drug efflux activity of an ABC transporter in vivo by in vitro selected DARPin binders Resistance to the macrocyclic lactone moxidectin is mediated in part by membrane transporter P-glycoproteins: Implications for control of drug resistant parasitic nematodes Crystal structure of a heterodimeric ABC transporter in its inward-facing conformation Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Moxidectin and the avermectins: Consanguinity but not identity Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? ABCG2-associated resistance to Hoechst 33342 and topotecan in a murine cell model with constitutive expression of side population characteristics Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes The controversial role of ABC transporters in clinical oncology. Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer Revisiting the role of ABC transporters in multidrug-resistant cancer. BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer Deficiency of multidrug resistance 2 contributes to cell transformation through oxidative stress Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Verapamil and rifampin effect on p-glycoprotein expression in hepatocellular carcinoma Chemoresistance: Intricate Interplay Between Breast Tumor Cells and Adipocytes in the Tumor Microenvironment Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells Biophysical Approaches Facilitate Computational Drug Discovery for ATP-Binding Cassette Proteins. Allosteric effects of ATP binding on the nucleotide-binding domain of a heterodimeric ATP-binding cassette transporter.
is cites work of	wds:Q21133734-C6AFED0D-F994-41A3-A36D-A1EBBF9F1E33 wds:Q35056738-8B15CAB4-55F4-4F22-B40D-8DAA9DB7B86A wds:Q37799220-F122B80B-C507-4BD4-AD29-002D4974AC2A wds:Q38025261-079A478F-0414-40BC-B963-63F2FA620996 wds:Q53793272-FD0DEB87-1E9B-4C86-9204-1C24856D99FF wds:Q45815416-94C3110D-6618-40DB-92FD-3E2278E78677 wds:Q36353160-6B020718-4ADD-43C9-BC24-1EE0E0CA01B5

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software